Medicine and HealthNature Medicine
A gut microbial signature for combination immune checkpoint blockade across cancer types
A. Gunjur, Y. Shao, et al.
Explore groundbreaking research by Ashray Gunjur and colleagues revealing that metagenomic sequencing of the gut microbiome can enhance predictions of immune checkpoint blockade response in rare cancers. This innovative study demonstrates how strain-resolved microbial data outperforms traditional analyses, hinting at tailored microbiome diagnostics for specific ICB regimens.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy
Y. Xiao, J. Chen, et al.
Medicine and Health
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial
T. Sonoda, Y. Umeda, et al.
Medicine and Health
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma
J. R. Björk, L. A. Bolte, et al.
Medicine and Health
A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer
Y. Ye, Q. Dai, et al.
